

# Validation data for Anti-CoV2RBD-bam-hIgG1 & Anti-CoV2RBD-ete-hIgG1


<https://www.invivogen.com/sars2-spike-lycov-mab>

For research use only

Version 21J22-NJ

Anti-CoV2RBD-bam-hIgG1 and Anti-CoV2RBD-ete-hIgG1 are recombinant monoclonal antibodies (mAbs) featuring the variable region of the LY-CoV555 (aka Bamlanivimab) and LY-CoV016 (aka Etesevimab) human mAbs, respectively. They both feature a human IgG1 constant region and they specifically target the SARS-CoV-2 Spike receptor-binding domain (RBD). The binding capacity of InvivoGen's Anti-CoV2RBD-bam-hIgG1 (**Figure 1A**) and Anti-CoV2RBD-ete-hIgG1 (**Figure 1B**) to a set of Spike variants has been validated using a Lucia luciferase-based ELISA.

## Binding of Anti-CoV2RBD-bam-hIgG1 and Anti-CoV2RBD-ete-hIgG1 to RBD variants



**Figure 1:** Anti-human or Anti-murine IgG F(ab')<sub>2</sub> fragment (2 µg/ml) was coated on an ELISA plate overnight. Anti-CoV2RBD-bam-hIgG1 or -mIgG2a (**A**), Anti-CoV2RBD-ete-hIgG1 or -mIgG2a (**B**) along with RBD-Lucia proteins (original, V2 and V4; 1 µg/ml) were added and incubated for 2 hours at room temperature. After washing (3x times), binding affinity was assessed by measuring the activity of Lucia luciferase in the supernatant using QUANTI-Luc™. Data are shown as a fold change over no antibody.

### TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873  
InvivoGen USA (International): +1 (858) 457-5873  
InvivoGen Europe: +33 (0) 5-62-71-69-39  
InvivoGen Asia: +852 3-622-34-80  
E-mail: [info@invivogen.com](mailto:info@invivogen.com)